An open-label, multicenter Phase I study to characterize the safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced hematological malignancies

Protocol: 
AAAQ7443
Phase: 
I

An open-label, multicenter Phase I study to characterize the safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced hematological malignancies

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on haematological cancer cells.

Are you Eligible? (Inclusion Criteria)

AML Inclusion:
1)Patients with a confirmed leukemia who are refractory to or have exhausted all available therapies.[If possible, patients with AML reported to have a high incidence of key biomarkers (e.g. MLL-rearranged AML) are to be preferably included]. Patients must have evidence of leukemia in bone marrow aspirate and bone marrow biopsy.

MM Inclusion:
1)Patients with confirmed multiple myeloma who are refractory/relapsed after a proteasome inhibitor/IMID (Immonomodulatory drugs) combination or who do not tolerate this therapy. MM patients must have been diagnosed by having met al three of the IMWG criteria at any point.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States